# Voydeya (danicopan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/danicopan

> The FDA approved Voydeya (danicopan), sponsored by ASTRAZENECA PLC (AZN), on March 29, 2024 for to treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Voydeya (danicopan) FDA approved?

Yes. The FDA approved Voydeya (danicopan), sponsored by ASTRAZENECA PLC (AZN), on March 29, 2024 for to treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria. FDA novel drug approvals: "Voydeya | danicopan | 3/29/2024 | To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuriaDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/danicopan)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/danicopan#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Voydeya (danicopan) |
| Codes |  |
| Sponsor | ASTRAZENECA PLC (AZN) https://sec-api.dev/companies/azn/catalysts |
| Indications | To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria, [Paroxysmal Nocturnal Hemoglobinuria](https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### March 29, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Voydeya | danicopan | 3/29/2024 | To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuriaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA218037 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240329, review_priority STANDARD; sponsor_name ALEXION PHARMS INC; product VOYDEYA (DANICOPAN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218037%22

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05389449 (A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT05389449

### August 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05389449 (A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT05389449

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06449001 (Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06449001

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Paroxysmal Nocturnal Hemoglobinuria; PNH; Extravascular Hemolysis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06449001 (Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-28 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06449001

## Same indication

- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [Oms906 study drug](https://sec-api.dev/pdufa/oms906-study-drug) (OMER)
- [Pozelimab](https://sec-api.dev/pdufa/pozelimab) (REGN)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)

Calendar months: [August 2026](https://sec-api.dev/fda-calendar/2026-08), [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/danicopan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Voydeya (danicopan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/danicopan

```bibtex
@misc{secapidev_pdufa_danicopan_20261116,
  title        = {Voydeya (danicopan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/danicopan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_danicopan_20261116","title":"Voydeya (danicopan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/danicopan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
